Biotherapeutic candidate discovery and development has been led by a diverse set of strategies used to identify antibody candidates. In addition to traditional hybridoma and phage approaches, NGS and synthetic DNA strategies are bringing the timelines to candidate selection to weeks rather than months or years.   Despite these varied workflows, common solutions such as HT-SPR can be implemented to eliminate bottlenecks. In this talk the role of HT-SPR and its successful enablement of discovery efforts against emerging public health threats such as COVID-19 will be explored as a technology in biotherapeutics discovery that is deployable in any workflow.